{
  "nctId": "NCT05416164",
  "briefTitle": "DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy",
  "officialTitle": "DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy",
  "protocolDocument": {
    "nctId": "NCT05416164",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2024-09-02",
    "uploadDate": "2025-03-21T08:40",
    "size": 972966,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05416164/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 595,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2022-10-07",
    "completionDate": "2037-05",
    "primaryCompletionDate": "2032-05",
    "firstSubmitDate": "2022-04-19",
    "firstPostDate": "2022-06-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Women, aged ≥ 18 years\n* Invasive HR positive/Her2 negative, Her2+ (ER/PR +/-) or TN breast cancer\n* Concurrent DCIS in pre-NST biopsy is allowed if there is no suspicion of extensive component i.e. absence of non-mass enhancement on pre-NST MRI, contrast-enhanced mammography or breast-specific gamma imaging and/or absence of calcifications on pre-NST mammography\n* Primary tumour (T) clinical stage cT1-2\n* Unifocal disease; confirmed by pre-NST MRI, contrast-enhanced mammography or breast-specific gamma imaging\n* Clinical nodal stage 0; absence of lymph node metastases should be confirmed by ultrasound or FDG-PET/CT\n* Neoadjuvant systemic treatment (NST)\n* Marker placed in breast tumour prior to NST\n* Breast conserving surgery performed, i.e. no mastectomy\n* Sentinel node biopsy performed before or after NST\n* Pathologic complete response in breast and lymph nodes, i.e. no residual tumour cells or DCIS detected\n* Written informed consent\n\nExclusion Criteria:\n\n* Primary tumour (T) clinical stage cT3-4\n* Pre- or post-NST diagnosis of nodal disease including isolated tumour cells\n* Patients without axillary ultrasound or FDG-PET/CT pre-NST\n* History of breast cancer or DCIS\n* Synchronous contralateral breast cancer or DCIS\n* Synchronous M1 disease\n* Carrier of gene mutation associated with increased risk of breast cancer, i.e. BRCA1, BRCA2, CHEK2, TP53 or PALB-2",
    "healthyVolunteers": false,
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Local recurrence",
        "description": "To show that radiotherapy after neoadjuvant systemic therapy and breast-conserving surgery can be omitted in T1-2N0 breast cancer patients who achieve pathologic complete response without compromising the 5 - year local recurrence rate (i.e, \\< 6% axillary recurrences within 5 years).",
        "timeFrame": "5 years"
      }
    ],
    "secondary": [
      {
        "measure": "Level of cancer worry",
        "description": "The patients' experienced level of cancer worry will be measured using the validated 8-item Cancer Worry Scale (i.e., low (Cancer Worry Scale score ≤ 13 at each assessment) and high (Cancer Worry Scale score ≥14 at each assessment)).",
        "timeFrame": "4 years"
      },
      {
        "measure": "Satisfaction reported by PROM (patient reported outcome measures)",
        "description": "The patients´experienced quality of life and satisfaction will be measured using the validated questionnaire EORTC-QLQ-C30 (Quality of life in cancer patients) and EORTC-QLQ-BR23 (Quality of life of patients with breast cancer)",
        "timeFrame": "4 years"
      },
      {
        "measure": "Overall survival",
        "timeFrame": "5 and 10 years"
      },
      {
        "measure": "Disease-specific survival",
        "timeFrame": "5 and 10 years"
      },
      {
        "measure": "Locoregional recurrence",
        "timeFrame": "5 years"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:53.495Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}